American School of Oncology

Breast Cancer: Metastatic to Liver

Other Professions Click Here to Continue

Release Date: March 4, 2003

Course Overview:

This case module discusses first-line therapies for the patient with breast cancer, metastatic to liver. It provides a review of research on various treatments for metastatic breast cancer and concludes with recommendations for treatments and the need for further exploration.

This activity will be valid until March 4, 2004.

Objective:

At the completion of this course, physicians will be better able to:

Faculty:

Eric Winer, MD
Director
Breast Oncology Center
Dana Farber Institute
Associate Professor of Medicine
Harvard Medicine School
Boston, Massachusetts

According to the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education, the faculty has been asked to disclose significant financial arrangements related to the content of this continuing medical education program. Dr. Winer conducts research supported by GlaxoSmithKline and Generated. Dr. Winer also participates in speaker's bureau supported by GlaxoSmithKilne and Generated.

Target Audience:

This educational activity has been designed to meet the educational needs of oncologists.

Accreditation Information:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Alabama School of Medicine and the Network for Oncology Communication and Research. The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Alabama School of Medicine designates this educational activity for a maximum of 0.25 Category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

Time to completion:

It will take 0.25 hours to complete this course.

Commercial Support:

Support for this program has been provided by an unrestricted educational grant from GlaxoSmithKline.

Participation in the course:

This course is offered in a case format online. Successful completion of the course and course evaluation will lead to an online certificate for 0.25 Category 1 credits that can be printed for your records. To receive credit, the course must be completed before March 4, 2004.

Physicians Click Here To Continue

Other Professions Click Here to Continue

The information provided by this service is intended for use as continuing education only. The user assumes full responsibility and all risks for the appropriate use of the information contained or provided by this NOCR service. The opinions of the expert discussant(s) expressed in this service are not necessarily those of the Network for Medical Communication & Research, LLC (NMCR). NMCR makes no warranty, expressed or implied, or assumes any legal liability for the accuracy, completeness, or usefulness of any information, product, or process disclosed.



	Breast Cancer: Metastatic to Liver Physicians Click Here To Continue Other Professions Click Here to Continue Release Date: March 4, 2003 Course Overview: This case module discusses first-line therapies for the patient with breast cancer, metastatic to liver. It provides a review of research on various treatments for metastatic breast cancer and concludes with recommendations for treatments and the need for further exploration. This activity will be valid until March 4, 2004. Objective: At the completion of this course, physicians will be better able to: Discuss research findings concerning the first-line therapies for breast cancer metastatic to liver. Describe current recommendations for treatment of breast cancer metastatic to liver. Faculty: Eric Winer, MD Director Breast Oncology Center Dana Farber Institute Associate Professor of Medicine Harvard Medicine School Boston, Massachusetts According to the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education, the faculty has been asked to disclose significant financial arrangements related to the content of this continuing medical education program. Dr. Winer conducts research supported by GlaxoSmithKline and Generated. Dr. Winer also participates in speaker's bureau supported by GlaxoSmithKilne and Generated. Target Audience: This educational activity has been designed to meet the educational needs of oncologists. Accreditation Information: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Alabama School of Medicine and the Network for Oncology Communication and Research. The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Alabama School of Medicine designates this educational activity for a maximum of 0.25 Category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity. Time to completion: It will take 0.25 hours to complete this course. Commercial Support: Support for this program has been provided by an unrestricted educational grant from GlaxoSmithKline. Participation in the course: This course is offered in a case format online. Successful completion of the course and course evaluation will lead to an online certificate for 0.25 Category 1 credits that can be printed for your records. To receive credit, the course must be completed before March 4, 2004. Physicians Click Here To Continue Other Professions Click Here to Continue The information provided by this service is intended for use as continuing education only. The user assumes full responsibility and all risks for the appropriate use of the information contained or provided by this NOCR service. The opinions of the expert discussant(s) expressed in this service are not necessarily those of the Network for Medical Communication & Research, LLC (NMCR). NMCR makes no warranty, expressed or implied, or assumes any legal liability for the accuracy, completeness, or usefulness of any information, product, or process disclosed. Network for Oncology Communication & Research (NOCR) is a division of Network for Medical Communication and Research, LLC (NMCR).